Key result
The North American FCS Score ≥45 correctly identified 95.5% of patients with genetically confirmed familial chylomicronemia syndrome.
Why the study?
Patients with familial chylomicronemia syndrome are often misdiagnosed, and the sensitivity of the North American FCS Score to identify patients likely to have positive DNA testing had not been quantified.
Does the North American FCS Score accurately identify patients with genetically confirmed familial chylomicronemia syndrome?
Cross-Sectional (n=66)
Does the North American FCS Score accurately identify patients with genetically confirmed familial chylomicronemia syndrome?
The NAFCS Score ≥45 demonstrates strong concordance with genetic diagnosis of FCS, supporting its use as a diagnostic tool in clinical practice.
NAFCS Score performance in genetically confirmed FCS remains uncertain; larger validation studies needed before clinical adoption.
BACKGROUND: Patients with familial chylomicronemia syndrome (FCS) are often misdiagnosed. A positive genetic diagnosis is considered definitive, but clinical scoring systems can also identify affected patients. The North American FCS (NAFCS) Score is intended to identify patients likely to have positive DNA testing, but its sensitivity has not been quantified. OBJECTIVE: To evaluate NAFCS Scores in patients from the Balance study. METHODS: We calculated NAFCS Scores in 66 patients with genetically confirmed FCS from the Balance study of olezarsen. RESULTS: We found that 95.5% (63/66) and 74.2% (49/66) of patients had NAFCS Scores ≥45 ("likely FCS") and ≥60 ("definite FCS"), respectively. In contrast, no patient had a score <30 ("unlikely FCS"), while 4.5% (3/66) had scores between 30 and 44 ("uncertain FCS"). CONCLUSION: The strong concordance between NAFCS Score ≥45 and a positive genetic diagnosis of FCS suggests that either approach can be used for diagnosis except in "uncertain FCS" cases, which require genetic testing. The score might also clinically support an FCS diagnosis when genetic testing is indeterminate due to variants of unknown significance.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2025) conducted a cross-sectional in Familial chylomicronemia syndrome (FCS) (n=66). North American FCS (NAFCS) Score was evaluated on NAFCS Score ≥45 ('likely FCS'). The North American FCS Score ≥45 correctly identified 95.5% of patients with genetically confirmed familial chylomicronemia syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: